WuXi Biologics, a leading global Contract Research, Development and Manufacturing Organisation (CRDMO), has launched its Integrated Biologics CRDMO Centre located in the district of Fengxian in Shanghai.

The opening will add development and manufacturing capacity at the Centre, with end-to-end services for diversified biologics to accelerate global clients' project timelines, from process development, analytical development, drug product development and quality control to pilot-scale manufacturing, clinical drug substance and drug product manufacturing. This also marks WuXi Biologics' ninth operational site in China.

Construction on the 1.6 million-square-foot Integrated Biologics CRDMO Centre began in November 2018. Initial phase, which became operational in 2020, provides an entire range of biologics research services from target evaluation, reagent generation, antibody generation, lead optimisation, complex biologics discovery, Pre-Clinical Candidates (PCC) identification to Investigational New Drug (IND) candidate selection. It also offers proprietary technology platforms WuXiBody and SDarBody for bispecific and multispecific antibodies discovery respectively.

This opening includes drug substance facility (MFG17) and two drug product facilities (DP14 and DP15) which are designed for maximum flexibility to meet global clients' demand for clinical drug substance and drug product manufacturing of their innovative biologics at various scales and volumes. These facilities will further enhance the company's clinical manufacturing network and ensure robust node of global capacity after their GMP release in 2023.